AbbVie's fast-growing JAK inhibitor Rinvoq has been cleared for alopecia areata in the EU, the first market for the hair loss ...

A dual GLP-1 and glucagon agonist developed by Altimmune has been shown to reduce drinking in people with alcohol use ...

A US judge has ordered that Novo Nordisk must face some allegations in court that it defrauded investors by making misleading ...

A blood test for tuberculosis that could make it easier to detect people with the infection and help save lives has shown ...

Biogen's second-quarter results show that sales of Alzheimer's disease therapy Leqembi are continuing to ramp up, driven by a new formulation that avoids the need for infusion clinic visits.

2025 is going to be a year of great change. At a macro level, political and geopolitical shifts around the world will reshape relations. Regulation and deregulation may alter processes. And any one of ...

Eli Lilly is still celebrating the FDA approval of its amyloid-directed Alzheimer's therapy Kisunla but has had less fortune with a candidate against tau, another well-established drug target for the ...

Recordati has received an unsolicited takeover offer from private equity group CVC Capital Partners that, if completed, would delist the pharma group from the Italian stock exchange. The €52-per-share ...

France's financial fraud office launched a raid on Sanofi's headquarters in Paris as part of an investigation into a financing deal provided by French bank Société Générale. The Parquet National ...

In a major shake-up of its UK operations, GSK has started building a brand new R&D centre in Cambridge and will transfer operations there from its current site in Stevenage, Hertfordshire, which has ...

GSK has garnered FDA approval for its pentavalent meningococcal vaccine Penmenvy, tipped as one of its major launches for 2025 and a rival to Pfizer's first-to-market Penbraya. The shot protects ...

Bavarian Nordic has repeated a recommendation that its shareholders accept a takeover offer from an investment consortium, saying updated terms are "fair and attractive." The Danish biopharma company ...